[HTML][HTML] CTOTC-08: A multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant …
SC Sweet, B Armstrong, J Blatter, H Chin… - American Journal of …, 2022 - Elsevier
We conducted a randomized, placebo-controlled, double-blind study of pediatric lung
transplant recipients, hypothesizing that rituximab plus rabbit anti-thymocyte globulin
induction would reduce de novo donor-specific human leukocyte antigen antibodies (DSA)
development and improve outcomes. We serially obtained clinical data, blood, and
respiratory samples for at least one year posttransplant. We analyzed peripheral blood
lymphocytes by flow cytometry, serum for antibody development, and respiratory samples for …
transplant recipients, hypothesizing that rituximab plus rabbit anti-thymocyte globulin
induction would reduce de novo donor-specific human leukocyte antigen antibodies (DSA)
development and improve outcomes. We serially obtained clinical data, blood, and
respiratory samples for at least one year posttransplant. We analyzed peripheral blood
lymphocytes by flow cytometry, serum for antibody development, and respiratory samples for …